357 related articles for article (PubMed ID: 28285448)
1. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Kutoh E; Wada A; Murayama T; Takizawa Y
Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
[TBL] [Abstract][Full Text] [Related]
2. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Kutoh E; Murayama T; Wada A; Hirate M
Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
[TBL] [Abstract][Full Text] [Related]
3. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hirate M
Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
5. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
7. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
8. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
[TBL] [Abstract][Full Text] [Related]
10. Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2020 Mar; 48(2):68-74. PubMed ID: 32098545
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Ozawa E; Kurihara R; Akiyama M
Drug Res (Stuttg); 2023 Jun; 73(5):279-288. PubMed ID: 36882112
[TBL] [Abstract][Full Text] [Related]
13. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
[TBL] [Abstract][Full Text] [Related]
14. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
16. Complementary effects on glycaemic and non-glycaemic parameters between responders and non-responders treated with pioglitazone and canagliflozin in drug-naive subjects with type 2 diabetes.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Int J Clin Pract; 2021 Dec; 75(12):e14914. PubMed ID: 34551185
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
19. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Inagaki N; Kondo K; Yoshinari T; Takahashi N; Susuta Y; Kuki H
Expert Opin Pharmacother; 2014 Aug; 15(11):1501-15. PubMed ID: 25010793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
